# Amneal Pharmaceuticals, Inc.: Form 10-Q for the period ended Sep 30, 2024

- Company: [Amneal Pharmaceuticals, Inc.](/companies/amrx.md) (CIK 1723128)
- Form: 10-Q
- Filed: 2024-11-12
- Accepted by EDGAR: Nov 12, 2024, 16:17 ET
- Period: 2024-09-30
- Accession: 0001723128-24-000042
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1723128/000172312824000042/amrx-20240930.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1723128/000172312824000042/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2024-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2024-07-01 to 2024-09-30 | $702.5m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months, 2024-01-01 to 2024-09-30 | $2.06bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months, 2024-07-01 to 2024-09-30 | $432.9m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months, 2024-01-01 to 2024-09-30 | $1.31bn | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months, 2024-07-01 to 2024-09-30 | $269.6m | us-gaap:GrossProfit |
| Gross profit | 9 months, 2024-01-01 to 2024-09-30 | $757.6m | us-gaap:GrossProfit |
| Research and development | 3 months, 2024-07-01 to 2024-09-30 | $61.1m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months, 2024-01-01 to 2024-09-30 | $136.4m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months, 2024-07-01 to 2024-09-30 | $118.7m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months, 2024-01-01 to 2024-09-30 | $347.7m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2024-07-01 to 2024-09-30 | $88.8m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2024-01-01 to 2024-09-30 | $173.5m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2024-07-01 to 2024-09-30 | $3.7m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2024-01-01 to 2024-09-30 | $13.4m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2024-07-01 to 2024-09-30 | −$156.0k | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2024-01-01 to 2024-09-30 | −$85.8m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2024-07-01 to 2024-09-30 | $0.00 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2024-01-01 to 2024-09-30 | −$0.28 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2024-07-01 to 2024-09-30 | $0.00 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2024-01-01 to 2024-09-30 | −$0.28 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2024-07-01 to 2024-09-30 | 309,647,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2024-01-01 to 2024-09-30 | 308,685,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2024-01-01 to 2024-09-30 | $177.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2024-01-01 to 2024-09-30 | $36.8m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2024-09-30 | $74.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2024-09-30 | $1.51bn | us-gaap:AssetsCurrent |
| Total assets | at 2024-09-30 | $3.46bn | us-gaap:Assets |
| Current liabilities | at 2024-09-30 | $1.10bn | us-gaap:LiabilitiesCurrent |
| Long-term debt | at 2024-09-30 | $2.17bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2024-09-30 | $224.7m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | at 2024-09-30 | −$93.4m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 45,111 characters.

Amneal Pharmaceuticals, Inc. (the “Company”, “we,” “us,” or “our”) is a global pharmaceutical company that develops, manufactures, markets, and distributes a diverse portfolio of essential medicines, including retail generics, injectables, biosimilars and specialty branded pharmaceuticals. We operate principally in the United States (“U.S.”), India, and Ireland, and sell to wholesalers, distributors, hospitals, governmental agencies, chain pharmacies and individual pharmacies, either directly or indirectly.

The following discussion and analysis contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors, including those set forth under Item 1A. *Risk Factors* in our 2023 Annual Report on Form 10-K and under the heading *Cautionary Note Regarding Forward-Looking Statements* included elsewhere in this Quarterly Report on Form 10-Q.

The following discussion and analysis for the three and nine months ended September 30, 2024 should also be read in conjunction with the consolidated financial statements and related notes thereto included elsewhere in this Quarterly Report on Form 10-Q and with our audited consolidated financial statements for the year ended December 31, 2023 included in our 2023 Annual Report on Form 10-K.

### Overview

We have three reportable segments: Generics, Specialty, and AvKARE.

#### Generics

Our Generics segment includes approximately 270 product families covering an extensive range of dosage forms and delivery systems, including both immediate and extended release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, ophthalmics, films, transdermal patches and topicals. We focus on developing products with substantial barriers-to-entry due to complex drug formulations or manufacturing, or legal or regulatory challenges. Generic products, particularly in the U.S., generally contribute most significantly to revenues and gross margins at the time of their launch, and even more so in periods of market exclusivity, or in periods of limited generic competition. As such, the timing of new product introductions can have a significant impact on our financial results. The entrance into the market of additional competition generally has a negative impact on the volume and/or pricing of the affected products. Additionally, pricing is determined by market place dynamics and is often affected by factors outside of our control.

#### Specialty

Our Specialty segment is engaged in the development, promotion, sale and distribution of proprietary branded pharmaceutical products, with a focus on products addressing central nervous system disorders, including Parkinson’s disease, and endocrine disorders. Our portfolio of products includes RYTARY® (extended release oral capsule formulation of carbidopa-levodopa), CREXONT® (combination of carbidopa and levodopa extended release capsules), UNITHROID® (levothyroxine sodium), and ONGENTYS® (opicapone). RYTARY® is indicated for the treatment of Parkinson’s disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication. On August 7, 2024, the FDA approved our new drug application for CREXONT®, previously referred to as IPX203. We began selling CREXONT®, which is indicated for the treatment of Parkinson’s disease, in September 2024. UNITHROID®, indicated for the treatment of hypothyroidism, is sold under a license and distribution agreement with Jerome Stevens Pharmaceuticals, Inc. ONGENTYS® is an add-on treatment to carbidopa/levodopa in patients with Parkinson’s disease experiencing “Off” episodes, which we commenced selling in early 2024 under a license agreement with BIAL-Portela & Ca., S.A.

Our Specialty products are marketed through skilled specialty sales and marketing teams, who call on neurologists, movement disorder specialists, endocrinologists and primary care physicians in key markets throughout the U.S. Our Specialty segment also has a number of product candidates that are in varying stages of development.

For Specialty products, the majority of the product’s commercial value is usually realized during the period in which the product has market exclusivity. In the U.S., when market exclusivity expires and generic versions of a product are approved and marketed, there can often be very substantial and rapid declines in the branded product’s sales.

#### AvKARE

Our AvKARE segment provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies, predominantly focused on the U.S. Department of Defense and the U.S. Department of Veterans Affairs. AvKARE is a re-packager of bottle and unit dose pharmaceuticals under the registered names of AvKARE and AvPAK. AvKARE is also a wholesale distributor of pharmaceuticals, over the counter drugs and medical supplies to its retail and institutional customers that are located throughout the U.S. focused primarily on offering 340b-qualified entities products to provide consistency in care and pricing.

#### The Pharmaceutical Industry

The pharmaceutical industry is highly competitive and highly regulated. As a result, we face a number of industry-specific factors and challenges, which can significantly impact our results. For a more detailed explanation of our business and its risks, refer to our *2023 Annual Report on Form 10-K,* as supplemented by Part II, Item 1A “Risk Factors” of our subsequent Quarterly Reports on Form 10-Q.

#### Inflation

While it is difficult to accurately measure the impact of inflation, we estimate our business will experience an increase in costs due to inflation of approximately $10.0 million to $15.0 million for the year ending December 31, 2024, excluding the impact of interest rates. Notwithstanding our estimates, rising inflationary pressures due to higher input costs, including higher material, transportation, labor and other costs, could exceed our expectations, which would further adversely impact our operating results in future periods.

### Results of Operations

### Comparison of Three Months Ended September 30, 2024 to Three Months Ended September 30, 2023

### Consolidated Results

The following table sets forth our summarized, consolidated results of operations for the three months ended September 30, 2024 and 2023 (in thousands):

|  | Three Months Ended September 30, 2024 | 2023 | Increase (Decrease) $% |  |
| --- | ---: | ---: | ---: | ---: |
| **Net revenue** | $702,468 | $620,040 | $82,428 | 13.3% |
| Cost of goods sold | 432,910 | 387,509 | 45,401 | 11.7% |
| **Gross profit** | 269,558 | 232,531 | 37,027 | 15.9% |
| Selling, general and administrative | 118,692 | 113,006 | 5,686 | 5.0% |
| Research and development | 61,097 | 41,375 | 19,722 | 47.7% |
| Intellectual property legal development expenses | 1,967 | 886 | 1,081 | 122.0% |
| Restructuring and other charges | 172 | 1,043 | (871) | (83.5)% |
| Change in fair value of contingent consideration | (1,030) | 3,120 | (4,150) | nm |
| Credit related to legal matters, net | (149) | (2,620) | 2,471 | (94.3)% |
| Other operating expense | — | 73 | (73) | (100.0)% |
| **Operating income** | 88,809 | 75,648 | 13,161 | 17.4% |
| Total other expense, net | (73,386) | (52,691) | (20,695) | 39.3% |
| Income before income taxes | 15,423 | 22,957 | (7,534) | (32.8)% |
| Provision for (benefit from) income taxes | 3,666 | (2,076) | 5,742 | nm |
| **Net income** | $11,757 | $25,033 | $(13,276) | (53.0)% |

nm - not meaningful

#### Net Revenue

Net revenue for the three months ended September 30, 2024 increased 13.3% from the prior year period, primarily due to:

- Growth in our Generics segment net revenue of $36.5 million, primarily due to new generic products launched in 2024 and 2023, which include biosimilars that contributed $5.7 million of year-over-year growth and other new generic products that contributed $34.8 million of year-over-year growth.
- Growth in our AvKARE segment net revenue of $27.6 million, primarily driven by growth in our distribution channel and government label channel which resulted from new product introductions.
- Growth in our Specialty segment net revenue of $18.3 million, primarily driven by a $16.8 million increase in our promoted Parkinson’s franchise, of which $4.3 million was comprised of sales of ONGENTYS®, which launched in January 2024, and initial sales of CREXONT®, which launched in September of 2024. Additionally, growth in our promoted endocrinology portfolio of $3.8 million was partially offset by declines in our non-promoted products.

#### Cost of Goods Sold and Gross Profit

Cost of goods sold increased 11.7% for the three months ended September 30, 2024 as compared to the prior year period. The increase in cost of goods sold was primarily due to increased AvKARE and Generics volume, increased plant and freight costs, and an increased inventory provision, partially offset by efficiencies in our supply costs.

Gross profit as a percentage of net revenue increased to 38.4% for the three months ended September 30, 2024 from 37.5% in the prior year period primarily as a result of the factors noted above.

#### Selling, General, and Administrative

Selling, general, and administrative (“SG&A”) expenses for the three months ended September 30, 2024 increased 5.0% as compared to the prior year period, primarily due to increases in employee compensation and promotion associated with ONGENTYS® and CREXONT®.

#### Research and Development

Research and development (“R&D”) expenses for the three months ended September 30, 2024 increased 47.7% as compared to the prior year period, primarily due to an increase in in-licensing and upfront milestone payments of $23.8 million, including $20.0 million associated with our exclusive license of Omalizumab (refer to *Note 19. Related Party Transactions* for additional information), partially offset by operating efficiencies in our infrastructure.

#### Change in Fair Value of Contingent Consideration

The $4.2 million decrease in the change in fair value of contingent consideration for the three months ended September 30, 2024 was primarily driven by a decrease in the associated forecasted revenues.

#### Credit Related to Legal Matters, Net

Credit related to legal matters, net was immaterial for the three months ended September 30, 2024. For the three months ended September 30, 2023, credit related to legal matters, net of $2.6 million primarily related to a $5.5 million gain from the settlement of patent infringement matters, partially offset by a $3.0 million charge for the settlement of a customer claim. Refer to *Note 17. Commitments and Contingencies* for additional information.

#### Total Other Expense, Net

Total other expense, net for the three months ended September 30, 2024 increased 39.3% as compared to the prior year period. The increase was primarily driven by a $14.6 million increase in interest expense as a result of higher rates on our variable-rate debt and an increase in the amount outstanding on our revolving credit facility and a $10.7 million increase in our tax receivable agreement liability (refer to *Note 5. Income Taxes* for additional information), partially offset by a gain resulting from favorable period-over-period foreign exchange rates primarily driven by the Euro.

#### Provision For (Benefit From) Income Taxes

For the three months ended September 30, 2024, our provision for income taxes and effective tax rate were $3.7 million and 23.8%, respectively. For the three months ended September 30, 2023, the Company’s benefit from income taxes and effective tax rate were $(2.1) million and (9.0)%, respectively. The period-over-period changes in the provision for income taxes and effective tax rate were primarily related to changes in the jurisdictional mix of income and a discrete Indian tax benefit of approximately $2.9 million from the utilization of a loss carryforward during the three months ended September 30, 2023.

### Generics

The following table sets forth results of operations for our Generics segment for the three months ended September 30, 2024 and 2023 (in thousands):

|  | Three Months Ended September 30, 2024 | 2023 | Increase (Decrease) $% |  |
| --- | ---: | ---: | ---: | ---: |
| **Net revenue** | $427,345 | $390,857 | $36,488 | 9.3% |
| Cost of goods sold | 249,342 | 236,268 | 13,074 | 5.5% |
| **Gross profit** | 178,003 | 154,589 | 23,414 | 15.1% |
| Selling, general and administrative | 30,951 | 33,538 | (2,587) | (7.7)% |
| Research and development | 57,099 | 35,103 | 21,996 | 62.7% |
| Intellectual property legal development expenses | 1,786 | 815 | 971 | 119.1% |
| Restructuring and other charges | 17 | 112 | (95) | (84.8)% |
| Credit related to legal matters, net | (149) | (2,500) | 2,351 | (94.0)% |
| Other operating expense | — | 73 | (73) | (100.0)% |
| **Operating income** | $88,299 | $87,448 | $851 | 1.0% |

#### Net Revenue

Generics net revenue for the three months ended September 30, 2024 increased 9.3% as compared to the prior year period, primarily due to new generic products launched in 2024 and 2023, which include biosimilars that contributed $5.7 million of year-over-year growth and other new generic products that contributed $34.8 million of year-over-year growth.

#### Cost of Goods Sold and Gross Profit

Generics cost of goods sold for the three months ended September 30, 2024 increased 5.5% as compared to the prior year period, primarily due to costs associated with increased sales volume and increased plant and freight costs, partially offset by efficiencies in our supply costs.

Generics gross profit as a percentage of net revenue increased to 41.7% for the three months ended September 30, 2024 from 39.6% in the prior year period primarily as a result of the factors noted above.

#### Selling, General, and Administrative

Generics SG&A expense for the three months ended September 30, 2024 decreased 7.7% as compared to the prior year period, primarily due to reduced legal fees, partially offset by increases in employee compensation.

#### Research and Development

Generics R&D expenses for the three months ended September 30, 2024 increased 62.7% as compared to the prior year period, primarily due to an increase in in-licensing and upfront milestone payments of $23.8 million, including $20.0 million associated with our exclusive license of Omalizumab (refer to *Note 19. Related Party Transactions* for additional information), partially offset by operating efficiencies in our infrastructure.

#### Credit Related to Legal Matters, Net

Credit related to legal matters, net was immaterial for the three months ended September 30, 2024. For the three months ended September 30, 2023, credit related to legal matters, net of $2.5 million primarily related to a $5.5 million gain from the settlement of patent infringement matters, partially offset by a $3.0 million charge for the settlement of a customer claim. Refer to *Note 17. Commitments and Contingencies* for additional information.

### Specialty

The following table sets forth results of operations for our Specialty segment for the three months ended September 30, 2024 and 2023 (in thousands):

|  | Three Months Ended September 30, 2024 | 2023 | Increase (Decrease) $% |  |
| --- | ---: | ---: | ---: | ---: |
| **Net revenue** | $115,638 | $97,304 | $18,334 | 18.8% |
| Cost of goods sold | 52,342 | 45,551 | 6,791 | 14.9% |
| **Gross profit** | 63,296 | 51,753 | 11,543 | 22.3% |
| Selling, general and administrative | 27,723 | 22,756 | 4,967 | 21.8% |
| Research and development | 3,998 | 6,272 | (2,274) | (36.3)% |
| Intellectual property legal development expenses | 181 | 71 | 110 | 154.9% |
| Restructuring and other charges | — | 931 | (931) | (100.0)% |
| Change in fair value of contingent consideration | (1,030) | 3,120 | (4,150) | nm |
| **Operating income** | $32,424 | $18,603 | $13,821 | 74.3% |

nm - not meaningful

#### Net Revenue

Specialty net revenue for the three months ended September 30, 2024 increased 18.8% compared to the prior year period, primarily driven by a $16.8 million increase in our promoted Parkinson’s franchise, of which $4.3 million was comprised of sales of ONGENTYS®, which launched in January 2024, and initial sales of CREXONT®, which launched in September of 2024. Additionally, growth in our promoted endocrinology portfolio of $3.8 million was partially offset by declines in our non-promoted products.

#### Cost of Goods Sold and Gross Profit

Specialty cost of goods sold for the three months ended September 30, 2024 increased 14.9% compared to the prior year period, primarily due to increased sales volume in our promoted products, partially offset by declines in our lower margin non-promoted products.

Specialty gross profit as a percentage of net revenue increased to 54.7% for the three months ended September 30, 2024 as compared to 53.2% in the prior year period, primarily due to growth in our higher margin promoted products.

#### Selling, General, and Administrative

Specialty SG&A expense for the three months ended September 30, 2024 increased 21.8% as compared to the prior year period, primarily due to increases in promotional costs associated with ONGENTYS® and CREXONT®.

#### Research and Development

Specialty R&D expense for the three months ended September 30, 2024 decreased 36.3% as compared to the prior year period, primarily due to reduced project spend of $0.7 million and reduced infrastructure costs.

#### Change in Fair Value of Contingent Consideration

The $4.2 million decrease in the change in fair value of contingent consideration for the three months ended September 30, 2024 was primarily driven by a decrease in the associated forecasted revenues.

### AvKARE

The following table sets forth results of operations for our AvKARE segment for the three months ended September 30, 2024 and 2023 (in thousands):

|  | Three Months Ended September 30, 2024 | 2023 | Increase $% |  |
| --- | ---: | ---: | ---: | ---: |
| **Net revenue** | $159,485 | $131,879 | $27,606 | 20.9% |
| Cost of goods sold | 131,226 | 105,690 | 25,536 | 24.2% |
| **Gross profit** | 28,259 | 26,189 | 2,070 | 7.9% |
| Selling, general and administrative | 15,145 | 14,313 | 832 | 5.8% |
| **Operating income** | $13,114 | $11,876 | $1,238 | 10.4% |

#### Net Revenue

AvKARE net revenue for the three months ended September 30, 2024 increased 20.9% as compared to the prior year period, primarily driven by growth in our distribution channel and government label channel which resulted from new product introductions.

#### Cost of Goods Sold and Gross Profit

AvKARE cost of goods sold for the three months ended September 30, 2024 increased 24.2% as compared to the prior year period, and gross profit as a percentage of net revenue decreased to 17.7% for the three months ended September 30, 2024 from 19.9% in the prior year period, primarily due to the increase in sales through our lower margin distribution channel and an increased inventory provision.

#### Selling, General and Administrative

AvKARE SG&A expense for the three months ended September 30, 2024 increased 5.8% as compared to the prior year period, primarily due to increases in employee compensation.

### Comparison of Nine Months Ended September 30, 2024 to Nine Months Ended September 30, 2023

### Consolidated Results

The following table sets forth our summarized, consolidated results of operations for the nine months ended September 30, 2024 and 2023 (in thousands):

|  | Nine Months Ended September 30, 2024 | 2023 | Increase (Decrease) $% |  |
| --- | ---: | ---: | ---: | ---: |
| **Net revenue** | $2,063,439 | $1,776,626 | $286,813 | 16.1% |
| Cost of goods sold | 1,305,874 | 1,145,888 | 159,986 | 14.0% |
| **Gross profit** | 757,565 | 630,738 | 126,827 | 20.1% |
| Selling, general and administrative | 347,749 | 320,672 | 27,077 | 8.4% |
| Research and development | 136,449 | 117,864 | 18,585 | 15.8% |
| Intellectual property legal development expenses | 3,993 | 3,350 | 643 | 19.2% |
| Restructuring and other charges | 1,862 | 1,635 | 227 | 13.9% |
| Change in fair value of contingent consideration | (930) | (787) | (143) | 18.2% |
| Charges (credit) related to legal matters, net | 94,909 | (1,039) | 95,948 | nm |
| Other operating income | — | (1,138) | 1,138 | (100.0)% |
| **Operating income** | 173,533 | 190,181 | (16,648) | (8.8)% |
| Total other expense, net | (213,227) | (146,990) | (66,237) | 45.1% |
| (Loss) income before income taxes | (39,694) | 43,191 | (82,885) | nm |
| Provision for (benefit from) income taxes | 13,440 | (1,431) | 14,871 | nm |
| **Net (loss) income** | $(53,134) | $44,622 | $(97,756) | nm |

nm - not meaningful

#### Net Revenue

Net revenue for the nine months ended September 30, 2024 increased 16.1% from the prior year period primarily due to:

- Growth in our Generics segment net revenue of $137.6 million, primarily due to new generic products launched in 2024 and 2023, which include biosimilars that contributed $47.0 million of year-over-year growth and other new generic products that contributed $90.2 million of year-over-year growth, and strong volume growth, partially offset by price erosion. Net revenue for the nine months ended September 30, 2023 included a non-recurring customer order of $21.0 million.
- Growth in our AvKARE segment net revenue of $110.3 million, primarily driven by growth in our distribution channel and government label channel which resulted from new product introductions.
- Growth in our Specialty segment net revenue of $38.9 million, primarily driven by a $35.6 million increase in our promoted Parkinson’s franchise, of which $11.8 million was comprised of sales of ONGENTYS®, which launched in January 2024, and initial sales of CREXONT®, which launched in September 2024. Additionally, growth in our promoted endocrinology portfolio of $11.1 million was partially offset by declines in our non-promoted products.

#### Cost of Goods Sold and Gross Profit

Cost of goods sold increased 14.0% for the nine months ended September 30, 2024 as compared to the prior year period. The increase in cost of goods sold was primarily due to increased AvKARE and Generics volume, increased plant and freight costs, and an increased inventory provision, partially offset by efficiencies in our supply costs. Cost of goods sold for the nine months ended September 30, 2023 included $11.0 million associated with the non-recurring customer order in our Generics segment discussed above.

Gross profit as a percentage of net revenue increased to 36.7% for the nine months ended September 30, 2024 from 35.5% in the prior year period, primarily as a result of the factors noted above.

#### Selling, General, and Administrative

SG&A expenses for the nine months ended September 30, 2024 increased 8.4% as compared to the prior year period, primarily due to increases in employee compensation, promotion associated with ONGENTYS® and CREXONT®, increased charges associated with our growing biosimilars, and annual fees assessed on branded prescription drug manufacturers, which are also applicable to certain of our generic products.

#### Research and Development

R&D expenses for the nine months ended September 30, 2024 increased 15.8% as compared to the prior year period, primarily due to an increase in in-licensing and upfront milestone payments of $26.6 million, including $20.0 million associated with our exclusive license of Omalizumab (refer to *Note 19. Related Party Transactions* for additional information), partially offset by operating efficiencies in our infrastructure.

#### Charges (Credit) Related to Legal Matters, Net

For the nine months ended September 30, 2024, charges related to legal matters, net of $94.9 million were primarily associated with a settlement in principle on the primary financial terms for a nationwide resolution to the opioids cases that have been filed and that might have been filed against us by political subdivisions and Native American tribes across the U.S. Refer to *Note 17. Commitments and Contingencies* for additional information.

For the nine months ended September 30, 2023, credit related to legal matters, net was $1.0 million, primarily comprised of $10.0 million from the settlement of patent infringement matters, partially offset by $4.1 million in charges associated with civil prescription opioid litigation, a $3.0 million charge for the settlement of a customer claim, and a $1.9 million charge for the settlement of a stockholder derivative lawsuit.

#### Total Other Expense, Net

Total other expense, net for the nine months ended September 30, 2024 increased 45.1% as compared to the prior year period. The increase was primarily driven by a $45.9 million increase in interest expense as a result of higher rates on our variable-rate debt and an increase in the amount outstanding on our revolving credit facility and a $24.8 million increase in our tax receivable agreement liability (refer to *Note 5. Income Taxes* for additional information), partially offset by a gain on the sale of a subsidiary in India of $3.8 million (refer to *Note 19. Related Party Transactions* for additional information).

#### Provision For (Benefit From) Income Taxes

For the nine months ended September 30, 2024, our provision for income taxes and effective tax rate were $13.4 million and (33.9)%, respectively, as compared to a benefit from income taxes and effective tax rate of $(1.4) million and (3.3)%, respectively, for the nine months ended September 30, 2023. The period-over-period changes in the provision for income taxes and effective tax rate primarily related to changes in the jurisdictional mix of income and a discrete Indian tax benefit of approximately $2.9 million from the utilization of a loss carryforward during the three months ended September 30, 2023.

### Generics

The following table sets forth results of operations for our Generics segment for the nine months ended September 30, 2024 and 2023 (in thousands):

|  | Nine Months Ended September 30, 2024 | 2023 | Increase (Decrease) $% |  |
| --- | ---: | ---: | ---: | ---: |
| **Net revenue** | $1,245,967 | $1,108,364 | $137,603 | 12.4% |
| Cost of goods sold | 750,167 | 692,008 | 58,159 | 8.4% |
| **Gross profit** | 495,800 | 416,356 | 79,444 | 19.1% |
| Selling, general and administrative | 95,663 | 89,178 | 6,485 | 7.3% |
| Research and development | 123,173 | 98,570 | 24,603 | 25.0% |
| Intellectual property legal development expenses | 3,778 | 3,240 | 538 | 16.6% |
| Restructuring and other charges | 70 | 211 | (141) | (66.8)% |
| Charges (credit) related to legal matters, net | 94,909 | (2,927) | 97,836 | nm |
| Other operating income | — | (1,138) | 1,138 | (100.0)% |
| **Operating income** | $178,207 | $229,222 | $(51,015) | (22.3)% |

nm - not meaningful

#### Net Revenue

Generics net revenue for the nine months ended September 30, 2024 increased 12.4% as compared to the prior year period, primarily due to new generic products launched in 2024 and 2023, which include biosimilars that contributed $47.0 million of year-over-year growth and other new generic products that contributed $90.2 million of year-over-year growth, and strong volume growth, partially offset by price erosion. Net revenue for the nine months ended September 30, 2023 included a non-recurring customer order of $21.0 million.

#### Cost of Goods Sold and Gross Profit

Generics cost of goods sold for the nine months ended September 30, 2024 increased 8.4% as compared to the prior year period, primarily due to costs associated with increased sales volume and increased plant and freight costs, partially offset by efficiencies in our supply costs. Cost of goods sold for the nine months ended September 30, 2023 included $11.0 million associated with the non-recurring customer order discussed above.

Generics gross profit as a percentage of net revenue increased to 39.8% for the nine months ended September 30, 2024 from 37.6% in the prior year period, primarily as a result of the factors noted above.

#### Selling, General, and Administrative

Generics SG&A expense for the nine months ended September 30, 2024 increased 7.3% as compared to the prior year period, primarily due to increases in employee compensation driven by infrastructure expansion and promotion associated with our biosimilar launches and the annual fees assessed on branded prescription drug manufacturers (applicable to certain of our generic products), partially offset by reduced legal fees.

#### Research and Development

Generics R&D expenses for the nine months ended September 30, 2024 increased 25.0% as compared to the prior year period, primarily due to an increase in in-licensing and upfront milestone payments of $26.6 million, including $20.0 million associated with our exclusive license of Omalizumab (refer to *Note 19. Related Party Transactions* for additional information), partially offset by operating efficiencies in our infrastructure.

#### Charges (Credit) Related to Legal Matters, Net

For the nine months ended September 30, 2024, charges related to legal matters, net of $94.9 million were primarily associated with a settlement in principle on the primary financial terms for a nationwide resolution to the opioids cases that have been filed and that might have been filed against us by political subdivisions and Native American tribes across the U.S. Refer to *Note 17. Commitments and Contingencies* for additional information.

For the nine months ended September 30, 2023, credit related to legal matters, net was $2.9 million, primarily comprised of $10.0 million from the settlement of patent infringement matters, partially offset by $4.1 million of charges associated with prescription opioid litigation and a $3.0 million charge for the settlement of a customer claim.

### Specialty

The following table sets forth results of operations for our Specialty segment for the nine months ended September 30, 2024 and 2023 (in thousands):

|  | Nine Months Ended September 30, 2024 | 2023 | Increase (Decrease) $% |  |
| --- | ---: | ---: | ---: | ---: |
| **Net revenue** | $324,913 | $285,976 | $38,937 | 13.6% |
| Cost of goods sold | 143,284 | 135,254 | 8,030 | 5.9% |
| **Gross profit** | 181,629 | 150,722 | 30,907 | 20.5% |
| Selling, general and administrative | 79,529 | 67,894 | 11,635 | 17.1% |
| Research and development | 13,276 | 19,294 | (6,018) | (31.2)% |
| Intellectual property legal development expenses | 215 | 110 | 105 | 95.5% |
| Restructuring and other charges | 1,024 | 1,013 | 11 | 1.1% |
| Change in fair value of contingent consideration | (930) | (787) | (143) | 18.2% |
| **Operating income** | $88,515 | $63,198 | $25,317 | 40.1% |

#### Net Revenue

Specialty net revenue for the nine months ended September 30, 2024 increased 13.6% as compared to the prior year period, primarily driven by a $35.6 million increase in our promoted Parkinson’s franchise, of which $11.8 million was comprised of sales of ONGENTYS®, which launched in January 2024, and initial sales of CREXONT®, which launched in September 2024. Additionally, growth in our promoted endocrinology portfolio of $11.1 million was partially offset by declines in our non-promoted products.

#### Cost of Goods Sold and Gross Profit

Specialty cost of goods sold for the nine months ended September 30, 2024 increased 5.9% as compared to the prior year period, primarily due to growth in our promoted products, partially offset by declines in our lower margin non-promoted products. Specialty gross profit as a percentage of net revenue increased to 55.9% for the nine months ended September 30, 2024 as compared to 52.7% in the prior year period due to growth in our higher margin promoted products.

#### Selling, General, and Administrative

Specialty SG&A expense for the nine months ended September 30, 2024 increased 17.1% as compared to the prior year period, primarily due to increases in promotional costs associated with ONGENTYS® and CREXONT®.

#### Research and Development

Specialty R&D expenses for the nine months ended September 30, 2024 decreased 31.2% as compared to the prior year period, primarily due to reduced project spend of $2.4 million and reduced infrastructure costs.

### AvKARE

The following table sets forth results of operations for our AvKARE segment for the nine months ended September 30, 2024 and 2023 (in thousands):

|  | Nine Months Ended September 30, 2024 | 2023 | Increase $% |  |
| --- | ---: | ---: | ---: | ---: |
| **Net revenue** | $492,559 | $382,286 | $110,273 | 28.8% |
| Cost of goods sold | 412,423 | 318,626 | 93,797 | 29.4% |
| **Gross profit** | 80,136 | 63,660 | 16,476 | 25.9% |
| Selling, general and administrative | 44,694 | 41,268 | 3,426 | 8.3% |
| **Operating income** | $35,442 | $22,392 | $13,050 | 58.3% |

#### Net Revenue

AvKARE net revenue for the nine months ended September 30, 2024 increased 28.8% as compared to the prior year period primarily driven by growth in our distribution channel and government label channel which resulted from new product introductions.

#### Cost of Goods Sold and Gross Profit

AvKARE cost of goods sold for the nine months ended September 30, 2024 increased 29.4% as compared to the prior year period, and gross profit as a percentage of net revenue decreased to 16.3% for the nine months ended September 30, 2024 from 16.7% in the prior year period, primarily due to the increase in sales through our lower margin distribution channel and an increased inventory provision.

#### Selling, General and Administrative

AvKARE SG&A expense for the nine months ended September 30, 2024 increased 8.3% as compared to the prior year period, primarily due to higher sales-related expenses, increases in employee compensation and higher professional fees, partially offset by reduced logistic costs.

### Liquidity and Capital Resources

Our primary source of liquidity is cash generated from operations, available cash on hand, and borrowings under debt financing arrangements (as defined and discussed in *Note 16. Debt* in our 2023 Annual Report on Form 10-K). We have access to $455.2 million of available capacity under the Amended New Revolving Credit Facility and $28.0 million of available capacity under the Amended Rondo Revolving Credit Facility as of September 30, 2024. We believe these sources are sufficient to fund our planned operations, meet our interest and contractual obligations, including acquisitions, and provide sufficient liquidity over the next 12 months from the date of filing of this Form 10-Q. However, our ability to satisfy our working capital requirements and debt obligations will depend upon economic conditions, our ability to negotiate and maintain satisfactory terms under our borrowing and debt facilities in the future, and demand for our products, which are factors that may be out of our control. Our primary uses of capital resources are to fund operating activities, including R&D expenses associated with new product filings, and pharmaceutical product manufacturing expenses, license payments, spending on production facility expansions, capital equipment, acquisitions, and legal settlements.

We estimate that we will invest approximately $60.0 million to $70.0 million during 2024 for capital expenditures to support and grow our existing operations, primarily related to investments in manufacturing facilities and equipment, and information technology.

#### Debt Instruments

Over the next 12 months, we expect to make substantial payments, including monthly interest and quarterly principal amounts due for our Term Loan Due 2028, monthly interest and the remaining principal balance on our Term Loan Due 2025, monthly interest on our Amended New Credit Facility, and contractual payments for leased premises. Refer to *Note 16. Debt, Note 18. Leases,* and *Commitments and Contractual Obligations under Part II, Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations* in our 2023 Annual Report on Form 10-K for additional information on our indebtedness and leases, respectively.

#### Settlement in Principle on Nationwide Civil Prescription Opioid Litigation

In late April 2024, we reached a nationwide settlement in principle on the primary financial terms, with no admission of wrongdoing, for a nationwide resolution to the opioids cases that have been filed and that might have been filed by Attorneys

General, political subdivisions and Native American tribes. Refer to *Note 17. Commitments and Contingencies* for additional information.

#### Tax Receivable Agreement

In 2018, we entered into a tax receivable agreement (“TRA”) for which we were generally required to pay the other holders of Amneal Common Units 85% of the applicable tax savings, if any, in U.S. federal and state income tax that we were deemed to realize as a result of certain tax attributes of their Amneal Common Units sold to us (or exchanged in a taxable sale) and that are created as a result of (i) the sales of their Amneal Common Units for shares of Class A common stock and (ii) tax benefits attributable to payments made under the TRA. As part of the Reorganization (as defined in *Note 1. Nature of Operations* in our 2023 Annual Report on Form 10-K), the TRA was amended to reduce our future obligation to pay 85% of the realized tax benefits subject to the TRA to 75% of such realized benefits. As of both September 30, 2024 and December 31, 2023, the contingent TRA liability, including the impact of the amendment, was approximately $185.0 million.

The timing and amount of any payments under the TRA may vary, depending upon a number of factors including the timing and amount of our taxable income, and the corporate tax rate in effect at the time of realization of our taxable income (the TRA liability is determined based on a percentage of the corporate tax savings from the use of the TRA’s attributes). Because the Amneal Group (as defined in *Item 1. Business* in the Company’s 2023 Annual Report on Form 10-K) has exchanged all of its Amneal Common Units pursuant to the Reorganization, the primary remaining factor that could increase the contingent TRA liability is an increase in the effective tax rate. Since the combined rate for federal and state and local income taxes, as of September 30, 2024, has not changed significantly since December 31, 2023, the contingent TRA liability has not changed significantly during 2024. In addition, any future payments under the TRA may create additional basis adjustments, which may result in an additional layer of depreciation and amortization allocable to the Company, resulting in additional TRA payments. The timing and amount of payments may also be accelerated under certain conditions, such as a change of control or other early termination event, which could give rise to our obligation to make TRA payments in advance of tax benefits being realized. For further information, refer to *Item 1A. Risk Factors* in our 2023 Annual Report on Form 10-K and *Note 5. Income Taxes* in this Form 10-Q.

#### Tax-Related Distributions

Prior to the Reorganization, Amneal was obligated to make tax distributions to the group, together with their affiliates and certain assignees, who owned Amneal when it was a private company (the “Members”). During the nine months ended September 30, 2023, the Company recorded net tax distributions to the Members of $57.6 million as a reduction of non-controlling interests. Subsequent to the Reorganization, the Company is no longer obligated to make tax distributions to the Members.

In 2020, we acquired a 65.1% controlling interest in both AvKARE Inc., a Tennessee corporation, now a limited liability company (“AvKARE, LLC”), and Dixon-Shane, LLC d/b/a R&S Northeast LLC, a Kentucky limited liability company (“R&S”). The sellers of AvKARE, LLC and R&S (the “AvKARE Sellers”) hold the remaining 34.9% interest in the holding company that directly owns the acquired companies (“Rondo”). We attribute 34.9% of the net income or loss associated with Rondo to redeemable non-controlling interests. During the nine months ended September 30, 2024 and 2023, we made cash tax distributions of $14.4 million and $10.3 million, respectively, to the AvKARE Sellers.

#### Cash Balances

As of September 30, 2024, our cash and cash equivalents consist of cash on deposit and highly liquid investments. A portion of our cash flows are derived outside the U.S. As a result, we are subject to market risk associated with changes in foreign exchange rates. We maintain cash balances at both U.S. based and foreign country based commercial banks. At various times during the year, our cash balances held in the U.S. may exceed amounts that are insured by the Federal Deposit Insurance Corporation (FDIC). We make our investments in accordance with our investment policy. The primary objectives of our investment policy are liquidity and safety of principal.

### Cash Flows

The following table sets forth our summarized, consolidated cash flows for the nine months ended September 30, 2024 and 2023 (in thousands):

| Net cash provided by (used in): | Nine Months Ended September 30, 2024 | 2023 | Increase (Decrease) $% |  |
| --- | ---: | ---: | ---: | ---: |
| Operating activities | $177,021 | $209,754 | $(32,733) | (15.6)% |
| Investing activities | (46,937) | (37,497) | (9,440) | 25.2% |
| Financing activities | (150,587) | (111,741) | (38,846) | 34.8% |
| Effect of exchange rate changes on cash | (259) | (136) | (123) | 90.4% |
| Net (decrease) increase in cash, cash equivalents, and restricted cash | $(20,762) | $60,380 | $(81,142) | (134.4)% |

#### Cash Flows from Operating Activities

Net cash provided by operating activities was $177.0 million for the nine months ended September 30, 2024 as compared to $209.8 million in the prior year period. The decrease in net operating cash flows for the nine months ended September 30, 2024 as compared to the prior year period was primarily driven by (i) lower collections of outstanding accounts receivable due to timing of sales in the quarter ended December 31, 2022, which benefited the nine months ended September 30, 2023 and (ii) receipt of a $21.4 million upfront payment associated with the license agreement with Orion Corporation during the nine months ended September 30, 2023, partially offset by (i) increased profitability adjusted for non-cash items, (ii) lower period over period payments associated with the Opana ER® antitrust litigation settlement and (iii) favorable working capital movements, most notably an increase in days payables outstanding.

#### Cash Flows from Investing Activities

Net cash used in investing activities for the nine months ended September 30, 2024 was $46.9 million as compared to $37.5 million in the prior year period. The period-over-period increase in net cash used in investing activities was primarily due to the payment of a $9.5 million sales-based milestone related to the licensing and supply agreement with mAbxience S.L. for its biosimilar candidate for Avastin® (bevacizumab) and higher capital expenditures, partially offset by $5.0 million in proceeds from the sale of a subsidiary in India to a subsidiary of Kashiv (refer to *Note 19. Related Party Transactions* for additional information).

#### Cash Flows from Financing Activities

Net cash used in financing activities was $150.6 million for the nine months ended September 30, 2024 as compared to $111.7 million in the prior year period. For the nine months ended September 30, 2024 and 2023, total debt repayments (including payments on the Sellers Notes), net of borrowings were $127.3 million and $38.8 million, respectively. The period-over-period increase in net cash used in financing activities was also due to an increase in employee payroll tax withholding on restricted stock unit vesting, partially offset by a period-over-period decrease in tax distributions to non-controlling interests of $53.4 million.

### Commitments and Contractual Obligations

Our contractual obligations are set forth in *Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations* contained in our 2023 Annual Report on Form 10-K. As of September 30, 2024, there have been no material changes to the disclosure presented in our 2023 Annual Report on Form 10-K.

### Off-Balance Sheet Arrangements

We did not have any off-balance sheet arrangements as of September 30, 2024.

### Critical Accounting Policies and Estimates

For a discussion of our critical accounting policies and estimates, see *Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations* in our 2023 Annual Report on Form 10-K. There have been no material changes to the disclosures presented in our 2023 Annual Report on Form 10-K.

### Recently Issued Accounting Standards

Recently issued accounting standards are discussed in *Note 2. Summary of Significant Accounting Policies.*

## Market risk

As filed, 198 characters.

There has not been any material change in our assessment of market risk as set forth in *Item 7A. Quantitative and Qualitative Disclosures About Market Risk*, in our 2023 Annual Report on Form 10-K.

## Controls and procedures

As filed, 2,885 characters.

### Disclosure Controls and Procedures

We maintain disclosure controls and procedures (as defined in Rule 13a-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) that are designed to ensure information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our Co-Chief Executive Officers and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

Our management, with the participation of our Co-Chief Executive Officers and Chief Financial Officer, evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form 10-Q. Based upon that evaluation, our Co-Chief Executive Officers and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of September 30, 2024.

### Changes in Internal Control over Financial Reporting

During the quarter ended September 30, 2024, there were no changes in our internal control over financial reporting which materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

### Limitations on the Effectiveness of Controls

Management, including our Co-Chief Executive Officers and Chief Financial Officer, does not expect that our disclosure controls and procedures or our system of internal control over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well designed or operated, can provide only reasonable, but not absolute, assurance that the objectives of the system of internal control are met. The design of our control system reflects the fact that there are resource constraints, and that the benefits of such control system must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control failures and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the intentional acts of individuals, by collusion of two or more people, or by management override of the controls. The design of any system of controls is also based in part on certain assumptions about the likelihood of future events, and there can be no assurance that the design of any particular control will always succeed in achieving its objective under all potential future conditions.

## Risk factors

As filed, 134 characters.

There have been no material changes to the disclosures presented in our 2023 Annual Report on Form 10-K under *Item 1A. Risk Factors.*

Filed Nov 12, 2024.
Source: SEC EDGAR, the filing index for accession 0001723128-24-000042. Last ingested by Listed: Nov 10, 2026, 02:45 ET. No prices; not investment advice.
